PDS Biotechnology (NASDAQ: PDSB)
$1.41
(-10.2%)
-$0.16
Price as of January 10, 2025, 4:00 p.m. ET
PDS Biotechnology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
PDS Biotechnology Company Info
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.